Beigene (NASDAQ:BGNE) has been given a $120.00 price target by research analysts at Maxim Group in a note issued to investors on Wednesday. The brokerage currently has a “buy” rating on the stock. Maxim Group’s target price would suggest a potential upside of 17.22% from the stock’s previous close.
A number of other equities analysts have also recently weighed in on the company. ValuEngine cut Beigene from a “hold” rating to a “sell” rating in a report on Wednesday. Cowen reaffirmed a “buy” rating on shares of Beigene in a report on Monday, December 11th. Robert W. Baird reaffirmed a “neutral” rating and issued a $83.00 price target (up previously from $58.00) on shares of Beigene in a report on Tuesday, November 14th. Zacks Investment Research cut Beigene from a “hold” rating to a “sell” rating in a report on Monday, November 13th. Finally, Morgan Stanley reaffirmed an “overweight” rating and issued a $95.00 price target (up previously from $87.00) on shares of Beigene in a report on Friday, October 6th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $96.67.
Shares of Beigene (NASDAQ:BGNE) traded up $1.56 during mid-day trading on Wednesday, hitting $102.37. The stock had a trading volume of 126,762 shares, compared to its average volume of 194,250. The firm has a market cap of $4,630.00 and a PE ratio of -78.15. The company has a current ratio of 9.33, a quick ratio of 9.27 and a debt-to-equity ratio of 0.20. Beigene has a fifty-two week low of $30.02 and a fifty-two week high of $118.95.
Beigene (NASDAQ:BGNE) last issued its quarterly earnings data on Monday, November 13th. The company reported $2.54 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.23 by $2.31. The company had revenue of $220.21 million during the quarter, compared to analyst estimates of $1.55 million. During the same period last year, the firm earned ($1.08) EPS. research analysts expect that Beigene will post -2.04 EPS for the current year.
In other Beigene news, CEO John Oyler sold 20,137 shares of the business’s stock in a transaction that occurred on Tuesday, December 26th. The stock was sold at an average price of $96.46, for a total transaction of $1,942,415.02. Following the completion of the sale, the chief executive officer now directly owns 110,179 shares in the company, valued at approximately $10,627,866.34. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, CMO Jane Huang sold 1,600 shares of the business’s stock in a transaction that occurred on Monday, November 20th. The stock was sold at an average price of $86.25, for a total value of $138,000.00. Following the sale, the chief marketing officer now owns 264,900 shares of the company’s stock, valued at $22,847,625. The disclosure for this sale can be found here. Insiders sold a total of 483,482 shares of company stock valued at $42,139,474 in the last ninety days. 19.90% of the stock is currently owned by insiders.
A number of large investors have recently bought and sold shares of the business. Hillhouse Capital Management Ltd. increased its stake in Beigene by 172.6% during the 2nd quarter. Hillhouse Capital Management Ltd. now owns 3,720,726 shares of the company’s stock worth $167,433,000 after buying an additional 2,355,906 shares in the last quarter. Orbimed Advisors LLC increased its stake in Beigene by 2.0% during the 3rd quarter. Orbimed Advisors LLC now owns 1,313,788 shares of the company’s stock worth $135,925,000 after buying an additional 26,200 shares in the last quarter. Canada Pension Plan Investment Board purchased a new stake in Beigene during the 3rd quarter worth approximately $62,076,000. Artal Group S.A. increased its stake in Beigene by 10.1% during the 2nd quarter. Artal Group S.A. now owns 400,000 shares of the company’s stock worth $18,000,000 after buying an additional 36,714 shares in the last quarter. Finally, Myriad Asset Management Ltd. increased its stake in Beigene by 16.6% during the 2nd quarter. Myriad Asset Management Ltd. now owns 385,585 shares of the company’s stock worth $17,351,000 after buying an additional 54,900 shares in the last quarter. Institutional investors own 55.32% of the company’s stock.
WARNING: This article was posted by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another website, it was copied illegally and reposted in violation of U.S. & international trademark and copyright legislation. The original version of this article can be accessed at https://www.americanbankingnews.com/2018/01/03/maxim-group-analysts-give-beigene-bgne-a-120-00-price-target.html.
BeiGene, Ltd. is a clinical-stage biopharmaceutical company. The Company is focused in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company had used its cancer biology platform to develop four clinical-stage drug candidates, such as BGB-3111, BGB-A317, BGB-290 and BGB-283, as of December 31, 2016.